Skip to Main Content

Paper Details

EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Oncogene
71
2018
-, ADP, BRCA, BRCA-mutant breast cancer, BRCA-mutant breast cells, BRCA-mutant ovarian cancer, BRCA-mutated breast and ovarian cancers, EZH2, H3, PAR, PARP, PARP1, PARPi, PARPi-untreated cells, PARPis, PRC2 complex, alkylating DNA, breast cancer, breast cancer cells, cancer, cancer stem cell, enhancer of zeste homolog 2, lysine, poly (ADP-ribose), poly (ADP-ribose) polymerase, poly-ADP-ribose, untreated cells
Author NameAffiliation
Jun YaoThe University of Texas MD Anderson Cancer Center
Gabriel N HortobagyiThe University of Texas MD Anderson Cancer Center
Mien-Chie HungThe University of Texas MD Anderson Cancer Center
Mien-Chie HungGraduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University
Mien-Chie HungAsia University
  • 1 - 5

Datasets

Release 1.2